Binary clinical trial risk - Phase III prostate cancer trial failure would eliminate primary value driver and likely require significant strategic pivot or wind-down
Regulatory approval uncertainty with FDA requiring additional trials or data beyond current Phase III program
Competitive pressure from established checkpoint inhibitors (Keytruda, Opdivo) and emerging cell therapies in oncology, potentially limiting market share even if approved
Reimbursement risk as payers increasingly scrutinize oncology drug cost-effectiveness, particularly for combination therapies
Large pharma competitors (Bristol Myers Squibb, Merck, Roche) with deeper pipelines, established commercial infrastructure, and ability to acquire or out-license competitive assets
Other viral immunotherapy platforms (Replimune, Oncolytics Biotech) advancing similar mechanisms with potentially faster timelines or broader indications
Prostate cancer treatment landscape evolving rapidly with PARP inhibitors, radioligand therapies, and novel hormone therapies potentially limiting CAN-2409 addressable market
Cash burn of approximately $30-40M annually with current $300M market cap suggests potential need for dilutive equity raise within 12-18 months depending on existing cash balance
Negative ROE of -29.2% and ROA of -24.3% reflect ongoing losses typical of clinical stage, but extended timeline to profitability increases dilution risk
At-the-market (ATM) equity programs or registered direct offerings common in small-cap biotech create persistent overhang and dilution for existing shareholders
StructuralCompetitiveBalance Sheet